How Will Botanix’s A$45 Million Raise Accelerate Sofdra® Growth and Cut Costs?

middle.news 9:52am on Tuesday 17th of February, 2026 AEDT • Healthcare Read Story

How Will Botanix’s A$45 Million Raise Accelerate Sofdra® Growth and Cut Costs?

9:52am on Tuesday 17th of February, 2026 AEDT Key Points A$45 million capital raising via two-tranche placement and underwritten SPP Strong Sofdra® growth – 62,500 prescriptions, A$21.2 million net revenue Negotiations underway to reduce API costs by 25–40% and diversify suppliers Options offered to investors exercisable at A$0.06, subject to shareholder approval Read Story

middle. Tap to Read Tap the card to read the full analysis about BOTANIX PHARMACEUTICALS (ASX:BOT) OPEN ARTICLE